OptimizeRx Corp — Director's Dealing 2022

Mar 3, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-03-01

Reporting Person: Inman Todd (Chief Technology Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-03-01	Stock Option	$43.24	A	4690	Acquired	2027-03-01	Common Stock (4690)	Direct
2022-03-01	Restricted Stock Units	$	A	2313	Acquired		Common Stock (2313)	Direct

Footnotes

F1: The stock option vests in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date.

F2: Each restricted stock unit represents a contingent right to receive one share of OptimizeRx common stock.

F3: The restricted stock units vest in three equal annual installments beginning March 1, 2023, the first anniversary of the grant date.